Abstract:In an effort to develop improved and effective targeted tyrosine kinase inhibitors (TKIs), a series of twelve novel compounds with the structural motif "(E)-4-(((1H-benzo[d]imidazol-2-yl)methyl)amino)-N′-(halogenated)benzylidenebenzohydrazide" were successfully synthesized in three steps, yielding high product yields (53–97%). Among this new class of compounds, 6c and 6h-j exhibited excellent cytotoxic effects against four different cancer cell lines, with half-maximal inhibitory concentration (IC50) values ranging from 7.82 to 21.48 μM. Notably, compounds 6h and 6i emerged as the most potent inhibitors, demonstrating significant activity against key kinases such as EGFR, HER2, and CDK2. Furthermore, compound 6h displayed potent inhibitory activity against AURKC, while 6i showed potent inhibitory effects against the mTOR enzyme, with excellent IC50 values comparable with well-established TKIs. The mechanistic study of lead compound 6i revealed its ability to induce cell cycle arrest and apoptosis in HepG2 liver cancer cells. This was accompanied by upregulation of pro-apoptotic caspase-3 and Bax and downregulation of anti-apoptotic Bcl-2. Additionally, molecular docking studies indicated that the binding interactions of compounds 6h and 6i with the target enzymes give multiple interactions. These results underscore the ability of compound 6i as a compelling lead candidate warranting further optimization and development as a potent multi-targeted kinase inhibitor, which could have significant implications for the treatment of various cancers. The detailed structural optimization, mechanism of action, and in vivo evaluation of this class of compounds warrant further investigation to assess their therapeutic potential.

Discovery of Azabenzimidazole Derivatives As Potent, Selective Inhibitors of TBK1/IKKε Kinases.

Discovery of 6-Aryl-azabenzimidaoles That Inhibit the TBK1/IKK-ε Kinases

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

Discovery of 1H-benzo[d]imidazole-(halogenated)Benzylidenebenzohydrazide Hybrids as Potential Multi-Kinase Inhibitors

Design, Synthesis and Biological Evaluation of Novel 3-Substituted Pyrazolopyrimidine Derivatives As Potent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Discovery of 1-Amino-1 H -imidazole-5-carboxamide Derivatives as Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Discovery of Pyrido[3,4-B]indol-1-one Derivatives As Novel Non-Covalent Bruton's Tyrosine Kinase (BTK) Inhibitors.

Design, synthesis, and biological evaluation of novel azaspirooxindolinone derivatives as potent inhibitors of ITK and BTK-positive cancers

Engineering Selectivity for Reduced Toxicity of Bacterial Kinase Inhibitors Using Structure-Guided Medicinal Chemistry

Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.

Design, Synthesis and Biological Evaluation of Novel Dithiocarbamate-Substituted Diphenylaminopyrimidine Derivatives As BTK Inhibitors

Design, synthesis, and biological evaluation of pyrrolopyrimidine derivatives as novel Bruton's tyrosine kinase (BTK) inhibitors

Discovery and Structure-Activity Relationship of Novel Diphenylthiazole Derivatives As BTK Inhibitor with Potent Activity Against B Cell Lymphoma Cell Lines.

Discovery and Biological Evaluation of Pyrimido[4,5-D]pyrimidine-2,4(1h,3h)-dione Derivatives As Potent Bruton’s Tyrosine Kinase Inhibitors

Discovery of Pyrrolo[1,2-A]quinoxalin-4(5h)-one Derivatives As Novel Non-Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Discovery and optimization of narrow spectrum inhibitors of Tousled like kinase 2 (TLK2) using quantitative structure activity relationships

Discovery and Structure Enabled Synthesis of 2,6-Diaminopyrimidin-4-one IRAK4 Inhibitors.

Structure-activity Relationship Investigation for Benzonaphthyridinone Derivatives As Novel Potent Bruton's Tyrosine Kinase (BTK) Irreversible Inhibitors.

Discovery of Pteridine-7(8H)-one Derivatives As Potent and Selective Inhibitors of Bruton's Tyrosine Kinase (BTK).

Discovery and Biological Evaluation of N5-substituted 6,7-Dioxo-6,7-dihydropteridine Derivatives As Potent Bruton's Tyrosine Kinase Inhibitors.